Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoMed TherapeuticsGDTC +12.50%27 Median PS Value is $0.00 as of Jul. 26, 2026. GuruFocus rates GDTC with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 278 Biotechnology companies, CytoMed Therapeutics ranks worse than 359711.87% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for CytoMed Therapeutics's Median PS Value or its related term are showing as below:
GDTC's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
CytoMed Therapeutics (NAS:GDTC) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
CytoMed Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.99
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics Median PS Value Related Terms
CytoMed Therapeutics Median PS Value Historical Data
* Premium members only.
The historical data trend for CytoMed Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GDTC vs LEXX, INAB, TRAW: Median PS Value Comparison
For the Biotechnology subindustry, CytoMed Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CytoMed Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoMed Therapeutics (GDTC) has a Median PS Value of $0.00 as of Jul. 26, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CytoMed Therapeutics and its competitors. According to the industry distribution chart, CytoMed Therapeutics ranks #999999 out of 278 companies in the Biotechnology industry.
Is CytoMed Therapeutics' Median PS Value too high?
CytoMed Therapeutics' current Median PS Value is $0.00. Based on the distribution chart, CytoMed Therapeutics ranks #999999 out of 278 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoMed Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoMed Therapeutics' Median PS Value compare to LEXX and INAB?
According to the Biotechnology industry distribution chart, CytoMed Therapeutics ranks #999999 out of 278 companies for Median PS Value. This places CytoMed Therapeutics in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on CytoMed Therapeutics and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoMed Therapeutics's current Median PS Value is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoMed Therapeutics stock overvalued right now?
CytoMed Therapeutics (GDTC) has a current Median PS Value of $0.00. The current Median PS Value is $0.00. CytoMed Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For CytoMed Therapeutics (GDTC), the current Median PS Value is $0.00 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
27GF Score
Get the complete analysis for GDTC
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDTC has been successfully added to your 
